| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Psoralen treatment (10, 15, 20, and 25 μM; 24 hours) was sensitive to clear breast cancer cell (BCC) populations (ALDH- cells, ALDH+ cells, and commercial BSCS), with an IC50 ranging from 18 to 21 μM. On the other hand, MCF-12A cells treated with psoralidin (30 μM; 24 hours) were able to significantly induce ALDH- cells, ALDH+ cells, and commercial BCSC[2]. Psoralidin's effects on treating ALDH- and ALDH+ cells in AIDS [2]
|
|---|---|
| ln Vivo |
Psoralen (5 mg/kg) reduces inflammation in BALB/c infrared-irradiated lungs by modifying the expression of pro-inflammatory cytokines that are crucial in inflammation [1].
|
| Cell Assay |
Cell viability assay [2]
Cell Types: ALDH- cells, ALDH+ cells, commercial breast cancer stem cells (BSCS) and normal mammary epithelial cells (MCF-12A) Tested Concentrations: 10, 15 , 50 and 25. μM Incubation Duration: 24 hrs (hours) Experimental Results: IC50 for ALDH- cells, ALDH+ cells, commercial BCSC was 18 to 21 μM. Apoptosis analysis [2] Cell Types: ALDH- cells, ALDH+ cells and commercial BCSC Tested Concentrations: 20 and 30 μM Incubation Duration: 24 hrs (hours) Experimental Results: No obvious apoptosis was observed in all three cell types after 20 μM treatment death induction. However, at 30 μMin, 53.60%, 44.1%, and 45.9% of ALDH- cells, ALDH+ cells, and commercial BCSCs were apoptotic, respectively. |
| Animal Protocol |
Animal/Disease Models: balb/c (Bagg ALBino) mouse[1]
Doses: 5 mg/kg Route of Administration: intraperitoneal (ip) injection; 30 minutes before and 1 hour after IR irradiation (20 Gy). Experimental Results: Anti-inflammatory effects on mice irradiated with infrared rays. |
| References |
|
| Additional Infomation |
Psoralidin is a member of the class of coumestans that is coumestan substituted by hydroxy groups at positions 3 and 9 and a prenyl group at position 2 respectively. It has a role as a plant metabolite and an estrogen receptor agonist. It is a member of coumestans, a polyphenol and a delta-lactone. It is functionally related to a coumestan.
Psoralidin has been reported in Phaseolus lunatus, Dolichos trilobus, and other organisms with data available. See also: Cullen corylifolium fruit (part of). |
| Molecular Formula |
C20H16O5
|
|---|---|
| Molecular Weight |
336.34
|
| Exact Mass |
336.099
|
| CAS # |
18642-23-4
|
| PubChem CID |
5281806
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
458.8±34.0 °C at 760 mmHg
|
| Melting Point |
290-292°
|
| Flash Point |
231.3±25.7 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.689
|
| LogP |
5.03
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
554
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C2C([H])=C(C([H])=C([H])C=2C2C(=O)OC3C([H])=C(C(C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])=C([H])C=3C1=2)O[H])O[H]
|
| InChi Key |
YABIJLLNNFURIJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H16O5/c1-10(2)3-4-11-7-14-17(9-15(11)22)25-20(23)18-13-6-5-12(21)8-16(13)24-19(14)18/h3,5-9,21-22H,4H2,1-2H3
|
| Chemical Name |
3,9-dihydroxy-2-(3-methylbut-2-enyl)-[1]benzofuro[3,2-c]chromen-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~148.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (6.18 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9732 mL | 14.8659 mL | 29.7318 mL | |
| 5 mM | 0.5946 mL | 2.9732 mL | 5.9464 mL | |
| 10 mM | 0.2973 mL | 1.4866 mL | 2.9732 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
